Table 1 Patients’ characteristics
Characteristic | All pts. | Initial diagnosis | PSA relapse | PSA persistence |
|---|---|---|---|---|
Number | 129 | 20 | 49 | 60 |
Age (years; median, range) | 72 (47–86) | 76 (53–86) | 74 (50–83) | 69 (47–83) |
Gleason Score [pts] | ||||
 6 | 11 (8.5%) | 3 (15%) | 7 (14.3%) | 1 (1.7%) |
 7a | 27 (20.9%) | 3 (15%) | 19 (38.8%) | 5 (8.3%) |
 7b | 37 (28.7%) | 6 (30%) | 11 (22.4%) | 20 (33.3%) |
 8 | 18 (14%) | 3 (15%) | 7 (14.3%) | 8 (13.3%) |
 9 | 34 (26.4%) | 5 (25%) | 5 (10.2%) | 24 (40.0%) |
 10 | 2 (1.6%) | – | – | 2 (3.3%) |
Risk group (D’Amico) [pts] | ||||
 low | 5 (3.9%) | 1 (5.0%) | 3 (6.1%) | 1 (1.7%) |
 intermediate | 21 (16.3%) | 2 (10.0%) | 13 (26.5%) | 6 (10.0%) |
 high | 103 (79.8%) | 17 (85%) | 33 (67.3%) | 53 (88.3%) |
PSMA PET positive [pts] | 92 (71.3%) | 20 (100%) | 27 (55.1%) | 45 (75%) |
PSA PRE-PSMA PET [ng/ml] (median/mean, range) | 0.86/6.04 (0.13–150.00) | 12.4/27.28 (0.14–150.0) | 0.49/1.00 (0.15–6.24) | 0.99/3.08 (0.13–39.2) |
PSA doubling time | ||||
  ≤ 10 months | 81 (74.3%) | – | 21 (42.9%) | 60 (100%) |
  > 10 months | 28 (25.7%) | – | 28 (57.1%) | – |
ADT at time of PET [pts] | 14 (10.9%) | 2 (10%) | 4 (8.2%) | 8 (13.3%) |
Activity of 68Ga-PSMA-HBED-CC [MBq] (mean, range) | 190.43 (87–293) | 197.50 (100–293) | 192.07 (94–293) | 186.85 (87–286) |